Please ensure Javascript is enabled for purposes of website accessibility

BioSante Waves the White Flag

By Dave Williamson - Updated Apr 7, 2017 at 12:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It looks like this is the end of the line for BioSante as we know it. After dissapointing results from a phase 3 trial when BioSante's lead drug, LibiGel, failed to beat a placebo, shares cratered and never recovered. Now comes today's news that BioSante will be merging with ANI Pharmaceuticals, with ANI gaining control of the company. This video takes a closer look at the merger and what it means for investors.

Many investors are attracted to BioSante and biotechs like it since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

Dave Williamson has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ANI Pharmaceuticals, Inc. Stock Quote
ANI Pharmaceuticals, Inc.
ANIP
$38.01 (0.45%) $0.17
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$11.03 (-1.52%) $0.17
Celgene Corporation Stock Quote
Celgene Corporation
CELG
Jazz Pharmaceuticals plc Stock Quote
Jazz Pharmaceuticals plc
JAZZ
$158.72 (-0.96%) $-1.54
Alkermes plc Stock Quote
Alkermes plc
ALKS
$26.45 (-0.56%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.